Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers

Rosa Antonijoan, Jimena Coimbra, Consuelo García-Gea, Montserrat Puntes, Ignasi Gich, Cristina Campo, Román Valiente, Luis Labeaga

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Objective: To compare the peripheral antihistaminic activity of bilastine, rupatadine and desloratadine in inhibiting the histamine-induced wheal and flare (W&F) response. Research design and methods: Twenty-four healthy volunteers aged 18–40 years participated in this crossover, randomized, double-blind, placebo-controlled clinical study. Subjects received single doses of bilastine 20 mg, desloratadine 5 mg, rupatadine 10 mg and placebo. W&F responses induced by intradermal injection of histamine 5 μg were evaluated before treatment (basal value) and at 0.5, 1, 2, 4, 6, 9, 12 and 24 hours after treatment. Fifteen minutes after histamine injection, W&F surface areas (cm2) were quantified using the Visitrak System. Itching sensation was evaluated using a 100 mm visual analog scale. EudraCT number: 2015-000790-13. Main outcome measures: The primary outcome measure was the percentage reduction in W&F areas after each active treatment compared with corresponding basal values. Results: Bilastine induced the greatest inhibition in wheal area and was significantly superior to desloratadine and rupatadine from 1 to 12 hours (both p <.001). Rupatadine and desloratadine were better than placebo without differences between them. Maximum wheal inhibition occurred at 6 hours (bilastine 83%, desloratadine 38%, rupatadine 37%). Onset of action was 1 hour for bilastine and 4 hours for desloratadine and rupatadine. Bilastine was significantly superior to desloratadine and rupatadine for flare inhibition from 1–24 hours (both p <.001) with an onset of action at 30 minutes. Bilastine was significantly better than desloratadine (2–12 hours; at least p <.05) and rupatadine (2–9 hours; at least p <.01) for reducing itching sensation. Neither desloratadine nor rupatadine significantly reduced itching compared to placebo. All active treatments were well tolerated. Conclusions: Bilastine 20 mg induced significantly greater inhibition of the W&F response compared with desloratadine 5 mg and rupatadine 10 mg throughout the 24 hour study period, and had the fastest onset of action. Only bilastine significantly reduced itching sensation versus placebo.
Original languageEnglish
Pages (from-to)129-136
JournalCurrent Medical Research and Opinion
Volume33
Issue number1
DOIs
Publication statusPublished - 2 Jan 2017

Keywords

  • Antihistamine
  • bilastine
  • desloratadine
  • histamine cutaneous challenge
  • rupatadine

Fingerprint

Dive into the research topics of 'Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers'. Together they form a unique fingerprint.

Cite this